JP2019511240A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019511240A5 JP2019511240A5 JP2018554450A JP2018554450A JP2019511240A5 JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5 JP 2018554450 A JP2018554450 A JP 2018554450A JP 2018554450 A JP2018554450 A JP 2018554450A JP 2019511240 A5 JP2019511240 A5 JP 2019511240A5
- Authority
- JP
- Japan
- Prior art keywords
- neural stem
- human neural
- disease
- stem cells
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 86
- 125000003729 nucleotide group Chemical group 0.000 claims description 66
- 210000001178 neural stem cell Anatomy 0.000 claims description 54
- 239000002773 nucleotide Substances 0.000 claims description 48
- 108020004414 DNA Proteins 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 32
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
- 108700019146 Transgenes Proteins 0.000 claims description 28
- 108090000623 proteins and genes Proteins 0.000 claims description 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 101710163270 Nuclease Proteins 0.000 claims description 20
- 230000008685 targeting Effects 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 108091033409 CRISPR Proteins 0.000 claims description 12
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 claims description 12
- 210000003169 central nervous system Anatomy 0.000 claims description 12
- 239000003550 marker Substances 0.000 claims description 12
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 201000008051 neuronal ceroid lipofuscinosis Diseases 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 8
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims description 8
- 230000000324 neuroprotective effect Effects 0.000 claims description 8
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 8
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 claims description 6
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 6
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 6
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 claims description 6
- 108090000099 Neurotrophin-4 Proteins 0.000 claims description 6
- 108010052285 Membrane Proteins Proteins 0.000 claims description 5
- 102000018697 Membrane Proteins Human genes 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 230000003018 neuroregenerative effect Effects 0.000 claims description 5
- 201000011452 Adrenoleukodystrophy Diseases 0.000 claims description 4
- 208000011403 Alexander disease Diseases 0.000 claims description 4
- CJLHTKGWEUGORV-UHFFFAOYSA-N Artemin Chemical compound C1CC2(C)C(O)CCC(=C)C2(O)C2C1C(C)C(=O)O2 CJLHTKGWEUGORV-UHFFFAOYSA-N 0.000 claims description 4
- 102000007371 Ataxin-3 Human genes 0.000 claims description 4
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims description 4
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims description 4
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 4
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 4
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 claims description 4
- 238000010354 CRISPR gene editing Methods 0.000 claims description 4
- 208000022526 Canavan disease Diseases 0.000 claims description 4
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 claims description 4
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 claims description 4
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 4
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 4
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 4
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 4
- 102000034615 Glial cell line-derived neurotrophic factor Human genes 0.000 claims description 4
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 claims description 4
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 claims description 4
- 108020005004 Guide RNA Proteins 0.000 claims description 4
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 claims description 4
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 claims description 4
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 4
- 102100037852 Insulin-like growth factor I Human genes 0.000 claims description 4
- 102100025947 Insulin-like growth factor II Human genes 0.000 claims description 4
- 102100026720 Interferon beta Human genes 0.000 claims description 4
- 108090000467 Interferon-beta Proteins 0.000 claims description 4
- 208000028226 Krabbe disease Diseases 0.000 claims description 4
- 208000034800 Leukoencephalopathies Diseases 0.000 claims description 4
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 4
- 102000004230 Neurotrophin 3 Human genes 0.000 claims description 4
- 108090000742 Neurotrophin 3 Proteins 0.000 claims description 4
- 102000003683 Neurotrophin-4 Human genes 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 206010048215 Xanthomatosis Diseases 0.000 claims description 4
- 229940112869 bone morphogenetic protein Drugs 0.000 claims description 4
- 229940077737 brain-derived neurotrophic factor Drugs 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims description 4
- 239000012636 effector Substances 0.000 claims description 4
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 4
- 208000016361 genetic disease Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 229940068935 insulin-like growth factor 2 Drugs 0.000 claims description 4
- 208000036546 leukodystrophy Diseases 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 230000004770 neurodegeneration Effects 0.000 claims description 4
- 231100000878 neurological injury Toxicity 0.000 claims description 4
- 239000003900 neurotrophic factor Substances 0.000 claims description 4
- 229940032018 neurotrophin 3 Drugs 0.000 claims description 4
- 239000000816 peptidomimetic Substances 0.000 claims description 4
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims description 4
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 4
- 230000008672 reprogramming Effects 0.000 claims description 4
- 210000001082 somatic cell Anatomy 0.000 claims description 4
- 210000001988 somatic stem cell Anatomy 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 230000002103 transcriptional effect Effects 0.000 claims description 4
- 210000004885 white matter Anatomy 0.000 claims description 4
- 101150017501 CCR5 gene Proteins 0.000 claims description 3
- 101150013707 HBB gene Proteins 0.000 claims description 3
- 230000002490 cerebral effect Effects 0.000 claims description 3
- 210000002435 tendon Anatomy 0.000 claims description 3
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 2
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000009575 Angelman syndrome Diseases 0.000 claims description 2
- 102100026376 Artemin Human genes 0.000 claims description 2
- 101710205806 Artemin Proteins 0.000 claims description 2
- 108010032947 Ataxin-3 Proteins 0.000 claims description 2
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 201000004569 Blindness Diseases 0.000 claims description 2
- 102000014814 CACNA1C Human genes 0.000 claims description 2
- 102100032219 Cathepsin D Human genes 0.000 claims description 2
- 102100035345 Cerebral dopamine neurotrophic factor Human genes 0.000 claims description 2
- 206010010356 Congenital anomaly Diseases 0.000 claims description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 claims description 2
- 102100039246 Elongator complex protein 1 Human genes 0.000 claims description 2
- 108010082945 Eukaryotic Initiation Factor-2B Proteins 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 102100028496 Galactocerebrosidase Human genes 0.000 claims description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 claims description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 claims description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 claims description 2
- 101000737775 Homo sapiens Cerebral dopamine neurotrophic factor Proteins 0.000 claims description 2
- 101000804964 Homo sapiens DNA polymerase subunit gamma-1 Proteins 0.000 claims description 2
- 101000813117 Homo sapiens Elongator complex protein 1 Proteins 0.000 claims description 2
- 101000860395 Homo sapiens Galactocerebrosidase Proteins 0.000 claims description 2
- 101000982010 Homo sapiens Myelin proteolipid protein Proteins 0.000 claims description 2
- 101000595929 Homo sapiens POLG alternative reading frame Proteins 0.000 claims description 2
- 101000729271 Homo sapiens Retinoid isomerohydrolase Proteins 0.000 claims description 2
- 101000875401 Homo sapiens Sterol 26-hydroxylase, mitochondrial Proteins 0.000 claims description 2
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims description 2
- 101000772888 Homo sapiens Ubiquitin-protein ligase E3A Proteins 0.000 claims description 2
- 101000867811 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1C Proteins 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000002569 Machado-Joseph Disease Diseases 0.000 claims description 2
- 101001129124 Mannheimia haemolytica Outer membrane lipoprotein 1 Proteins 0.000 claims description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 claims description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 claims description 2
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims description 2
- 102000003729 Neprilysin Human genes 0.000 claims description 2
- 108090000028 Neprilysin Proteins 0.000 claims description 2
- 102100033857 Neurotrophin-4 Human genes 0.000 claims description 2
- 108090000095 Neurotrophin-6 Proteins 0.000 claims description 2
- 102100021584 Neurturin Human genes 0.000 claims description 2
- 108010015406 Neurturin Proteins 0.000 claims description 2
- 101000761187 Odontomachus monticola U-poneritoxin(01)-Om1a Proteins 0.000 claims description 2
- 101150096217 PHYH gene Proteins 0.000 claims description 2
- 102100035196 POLG alternative reading frame Human genes 0.000 claims description 2
- 102000005327 Palmitoyl protein thioesterase Human genes 0.000 claims description 2
- 108020002591 Palmitoyl protein thioesterase Proteins 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 108010077056 Peroxisomal Targeting Signal 2 Receptor Proteins 0.000 claims description 2
- 102100032924 Peroxisomal targeting signal 2 receptor Human genes 0.000 claims description 2
- 102100036660 Persephin Human genes 0.000 claims description 2
- 102100039421 Phytanoyl-CoA dioxygenase, peroxisomal Human genes 0.000 claims description 2
- 241000206607 Porphyra umbilicalis Species 0.000 claims description 2
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 2
- 102100031176 Retinoid isomerohydrolase Human genes 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 108091006792 SLC20A2 Proteins 0.000 claims description 2
- 102000014105 Semaphorin Human genes 0.000 claims description 2
- 108050003978 Semaphorin Proteins 0.000 claims description 2
- 102100032419 Sodium-dependent phosphate transporter 2 Human genes 0.000 claims description 2
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 claims description 2
- 102100036325 Sterol 26-hydroxylase, mitochondrial Human genes 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 102100021947 Survival motor neuron protein Human genes 0.000 claims description 2
- 201000008188 Timothy syndrome Diseases 0.000 claims description 2
- 102100027059 Translation initiation factor eIF-2B subunit alpha Human genes 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 108010039203 Tripeptidyl-Peptidase 1 Proteins 0.000 claims description 2
- 102100034197 Tripeptidyl-peptidase 1 Human genes 0.000 claims description 2
- 102100030434 Ubiquitin-protein ligase E3A Human genes 0.000 claims description 2
- 239000012190 activator Substances 0.000 claims description 2
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 230000001919 adrenal effect Effects 0.000 claims description 2
- 208000017478 adult neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000000735 allogeneic effect Effects 0.000 claims description 2
- 206010001902 amaurosis Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 229960003638 dopamine Drugs 0.000 claims description 2
- 230000005782 double-strand break Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 108060002566 ephrin Proteins 0.000 claims description 2
- 102000012803 ephrin Human genes 0.000 claims description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002513 implantation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000003780 insertion Methods 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 claims description 2
- 210000005036 nerve Anatomy 0.000 claims description 2
- 230000001272 neurogenic effect Effects 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 claims description 2
- 229940097998 neurotrophin 4 Drugs 0.000 claims description 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 2
- 108010070453 persephin Proteins 0.000 claims description 2
- 238000004321 preservation Methods 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 230000008929 regeneration Effects 0.000 claims description 2
- 238000011069 regeneration method Methods 0.000 claims description 2
- 230000002207 retinal effect Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 230000035899 viability Effects 0.000 claims description 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 claims 1
- 208000005587 Refsum Disease Diseases 0.000 claims 1
- 208000030597 adult Refsum disease Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322652P | 2016-04-14 | 2016-04-14 | |
| US62/322,652 | 2016-04-14 | ||
| PCT/US2017/027504 WO2017180926A1 (en) | 2016-04-14 | 2017-04-13 | Genome editing of human neural stem cells using nucleases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019511240A JP2019511240A (ja) | 2019-04-25 |
| JP2019511240A5 true JP2019511240A5 (enExample) | 2020-05-14 |
| JP7197363B2 JP7197363B2 (ja) | 2022-12-27 |
Family
ID=60037918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554450A Active JP7197363B2 (ja) | 2016-04-14 | 2017-04-13 | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170298348A1 (enExample) |
| EP (1) | EP3443085B1 (enExample) |
| JP (1) | JP7197363B2 (enExample) |
| CN (1) | CN109312308A (enExample) |
| AU (2) | AU2017250683A1 (enExample) |
| CA (1) | CA3020181A1 (enExample) |
| SG (1) | SG11201808920RA (enExample) |
| WO (1) | WO2017180926A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| CN109804066A (zh) | 2016-08-09 | 2019-05-24 | 哈佛大学的校长及成员们 | 可编程cas9-重组酶融合蛋白及其用途 |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| AU2017342543B2 (en) | 2016-10-14 | 2024-06-27 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| KR20190127797A (ko) | 2017-03-10 | 2019-11-13 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 시토신에서 구아닌으로의 염기 편집제 |
| CA3057192A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| EP3724214A4 (en) | 2017-12-15 | 2021-09-01 | The Broad Institute Inc. | SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12281338B2 (en) | 2018-10-29 | 2025-04-22 | The Broad Institute, Inc. | Nucleobase editors comprising GeoCas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| DE112020001306T5 (de) | 2019-03-19 | 2022-01-27 | Massachusetts Institute Of Technology | Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| CN110075319A (zh) * | 2019-04-29 | 2019-08-02 | 白涛 | 一种抗遗传病生物导弹 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| EP4103177A4 (en) * | 2020-02-11 | 2024-03-27 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR THE TREATMENT AND/OR PREVENTION OF EYE DISEASES |
| US20230133201A1 (en) * | 2020-03-11 | 2023-05-04 | Remotor Therapeutics, Inc. | Methods and materials for disseminating a protein throughout the central nervous system |
| JP2023525304A (ja) | 2020-05-08 | 2023-06-15 | ザ ブロード インスティテュート，インコーポレーテッド | 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物 |
| EP4158041A4 (en) * | 2020-06-02 | 2024-09-25 | Catalent Pharma Solutions, LLC | CELL LINES WITH MULTIPLE DOCKING ZONES FOR GENE INSERTION |
| CN111925998A (zh) * | 2020-06-09 | 2020-11-13 | 广州再生医学与健康广东省实验室 | 模拟SARS-CoV-2感染的系统及其制备方法与应用 |
| WO2022163770A1 (ja) * | 2021-01-28 | 2022-08-04 | 国立研究開発法人理化学研究所 | ゲノム編集ツールの評価方法 |
| WO2023102712A1 (zh) * | 2021-12-07 | 2023-06-15 | 深圳市先康达生命科学有限公司 | 一种基因生物制剂及其制备方法和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7037719B1 (en) | 1999-02-12 | 2006-05-02 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US7105150B2 (en) | 1999-02-12 | 2006-09-12 | Stemcells California, Inc. | In vivo screening methods using enriched neural stem cells |
| US7217565B2 (en) | 1999-02-12 | 2007-05-15 | Stemcells California, Inc. | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| US20060099651A1 (en) | 2002-08-27 | 2006-05-11 | Nobuko Uchida | Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations |
| ES2828663T3 (es) * | 2012-04-18 | 2021-05-27 | Univ Leland Stanford Junior | Dirección genética no disruptiva |
| FI3597749T3 (fi) * | 2012-05-25 | 2023-10-09 | Univ California | Menetelmiä ja koostumuksia rna-ohjattua kohde-dna-modifikaatiota varten ja rna-ohjattua transkription modulaatiota varten |
| PT3363902T (pt) * | 2012-12-06 | 2019-12-19 | Sigma Aldrich Co Llc | Modificação e regulação de genoma baseadas em crispr |
| PT2784162E (pt) * | 2012-12-12 | 2015-08-27 | Broad Inst Inc | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
| WO2015057976A1 (en) * | 2013-10-17 | 2015-04-23 | Sangamo Biosciences, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
| CA2930590C (en) * | 2013-11-15 | 2021-02-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Engineering neural stem cells using homologous recombination |
| EP3152319A4 (en) * | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
-
2017
- 2017-04-13 EP EP17783170.8A patent/EP3443085B1/en active Active
- 2017-04-13 US US15/487,309 patent/US20170298348A1/en not_active Abandoned
- 2017-04-13 WO PCT/US2017/027504 patent/WO2017180926A1/en not_active Ceased
- 2017-04-13 JP JP2018554450A patent/JP7197363B2/ja active Active
- 2017-04-13 AU AU2017250683A patent/AU2017250683A1/en not_active Abandoned
- 2017-04-13 CN CN201780036763.3A patent/CN109312308A/zh active Pending
- 2017-04-13 SG SG11201808920RA patent/SG11201808920RA/en unknown
- 2017-04-13 CA CA3020181A patent/CA3020181A1/en active Pending
-
2023
- 2023-01-03 US US18/092,911 patent/US20230250423A1/en active Pending
- 2023-07-24 AU AU2023208065A patent/AU2023208065A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019511240A5 (enExample) | ||
| US20250257343A1 (en) | Nucleic acid-based therapeutics | |
| JP7197363B2 (ja) | ヌクレアーゼを使用するヒト神経幹細胞のゲノム編集 | |
| Ichim et al. | Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report | |
| Domanskyi et al. | Prospects of neurotrophic factors for Parkinson's disease: comparison of protein and gene therapy | |
| Garbossa et al. | New strategies for repairing the injured spinal cord: the role of stem cells | |
| Hannallah et al. | Gene therapy in orthopaedic surgery | |
| US20220340928A1 (en) | Vectors for the treatment of friedreich's ataxia | |
| Behl et al. | Gene therapy in the management of Parkinson’s disease: potential of GDNF as a promising therapeutic strategy | |
| Gupta et al. | Gene therapy in dentistry: Tool of genetic engineering. Revisited | |
| US20030045830A1 (en) | Gene therapy with chimeric oligonucleotides delivered by a method comprising a step of iontophoresis | |
| Phillips | Gene, stem cell, and future therapies for orphan diseases | |
| Saito et al. | Adenoviral GDNF gene transfer prevents motoneuron loss in the nucleus ambiguus | |
| RU2020125769A (ru) | Олигонуклеотиды для модуляции экспрессии tmem106b | |
| Yao et al. | Non-viral gene therapy for spinal cord regeneration | |
| Marr et al. | Insights into neurogenesis and aging: potential therapy for degenerative disease? | |
| Papadopoulos et al. | Gene therapies in clinical trials | |
| Isaac Chen et al. | Neural stem cells as biological minipumps: a faster route to cell therapy for the CNS? | |
| Cunha et al. | Chondroitinase ABC in spinal cord injury: advances in delivery strategies and therapeutic synergies | |
| Arora et al. | Gene therapies for neurodegenerative disease: current knowledge and challenges | |
| Bhagwat et al. | Neurogenesis: Gene-Based Strategies for Treating Ischemic Stroke | |
| Verhaagen et al. | Gene Therapy for Spinal Cord Injury | |
| O’Carroll et al. | Viral vector gene therapy approaches for regeneration and repair in spinal cord injury | |
| Li | Gene Therapy as a Frontier in Pharmacological Treatment | |
| Nakajima et al. | Targeted retrograde gene delivery into the injured spinal cord using recombinant adenovirus vector carrying neurotrophic factor gene |